206 research outputs found
High iron content of Ankaferd hemostat as a clue for its hemostatic action of red blood cell origin
No full textHaznedaroglu, Ibrahim C./0000-0001-8028-9462
Echocardiographic Dilemma: Misleading Thrombus Appearance Due to Cavitation With Intravascular Hemolysis on a Mechanical Prosthetic Valve
No full textEchocardiographic Dilemma: Misleading Thrombus Appearance Due to Cavitation With Intravascular Hemolysis on a Mechanical Prosthetic Valve Ibrahim Akpinar, MD, Muhammet Rasit Sayin, MD, Turgut Karabag, MD, Mehmet Emin Kalkan, MD, Sait Mesut Dogan, MD, Mustafa Aydin, MD, and Ibrahim C. Haznedaroglu, MD a Zonguldak Karaelmas University, Faculty of Medicine, Department of Cardiology, Zonguldak, Turkey b Ataturk State Hospital, Department of Cardiology, Zonguldak, Turkey c Hacettepe University, Faculty of Medicine, Department of Hematology, Ankara, Turke
Autoimmune hemolytic anemia in Philadelphia positive chronic myeloid leukemia with t(7;14) anomaly after 5 years of interferon alpha treatment
No full textKarakus, sema/0000-0001-7615-4581; Haznedaroglu, Ibrahim C./0000-0001-8028-9462; Haznedaroglu, Ibrahim C./0000-0001-8028-9462A 41-year-old woman, Philadelphia positive chronic myeloid leukemia patient, had progressive decline in hemoglobin levels. She had been receiving interferon alpha treatment for five years. Autoimmune hemolytic anemia was diagnosed. Subsequent bone marrow examination revealed translocation t(7;14). She was placed on prednisone treatment. The patient responded to prednisone as treatment for the hemolytic process. The result of a direct Coombs' test remained positive. The patient died shortly after the diagnosis of autoimmune hemolytic anemia. Autoimmune hemolytic anemia should be considered in the evaluation of chronic myeloid leukemia patients with a sudden decrease in hemoglobin levels
Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case
No full textUmit Yavuz Malkan, Gursel Gunes, Eylem Eliacik, Ibrahim Celalettin Haznedaroglu Department of Hematology, School of Medicine, Hacettepe University, Ankara, Turkey Abstract: Thalidomide may be used as a treatment option for pyoderma gangrenosum (PG) and myelodysplastic syndrome (MDS). Herein, we aimed to report a patient who was treated well with thalidomide and whose diagnosis was PG with MDS. A 61-year-old man with painless ecchymotic lesions in his right upper extremity was admitted to the hospital in Isparta, Turkey, in January 2015. The lesions were diagnosed as PG. In his anamnesis, it was found that he was diagnosed with MDS 6 years ago and had been treated with cyclosporine at 2×100 mg for 5 years, which was stopped in January 2015. Aspiration from liver lesion revealed the presence of Mycobacterium tuberculosis, so antituberculosis treatment was started. Bone marrow investigation revealed MDS-refractory anemia with excess blasts (7%). For lesions in bilateral upper extremities, thalidomide treatment was started at 50 mg/d. After 1 month from the initiation of thalidomide treatment, the lesions in upper extremities had disappeared. In the literature, there are some reports of patients with PG who were successfully treated with thalidomide. Our patient is a complicated case who simultaneously has MDS, PG, and tuberculosis infection. The reason for thalidomide usage in our patient was the need of immune modulation without immune suppression. Our patient has tolerated the drug well, and excellent response was obtained after 1 month of initiation of thalidomide treatment. To conclude, thalidomide is a very effective drug acting as an immune modulator, which is useful in the clinical management of both MDS and PG. Keywords: pyoderma gangrenosum, thalidomide, myelodysplastic syndrom
Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult
No full textMONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
No full textThe aim of oral tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is to get ideal hematological, cytogenetic, molecular responses at the critical time-points. The depth of the response obtained with TKI and time to achieve this response are important for the prediction of prognosis in the patient with CML. The high efficacy of the TKI treatment of CML has prompted the need for accurate methods to monitor response at levels below the landmark of CCyR. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available and has shown prognostic impact with regard to progression-free survival. European LeukemiaNet (ELN) molecular program harmonized the reporting of results according to the IS (Internatıonal harmonization of Scale) in Europe. The aim of this review is to outline monitoring the response to optimal TKI treatment based on the ELN CML 2013 recommendations from the clinical point of view as a physician. Careful cytogenetic and molecular monitoring could help selecting the most convenient TKI drug and to optimize TKI treatment. Excessive monitoring may have an economical cost but failure to optimize TKI treatment may result in CML disease acceleration and death
Clarification Letter Regarding the Gas Chromatography–Mass Spectrometry (GC-MS) Analyses of Ankaferd Hemostat
No full text
- …
